Schizophrenia is a serious neurodevelopmental disorder that often starts during adolescence. Current treatment guidelines (NICE, 2013) recommend atypical antipsychotics for adolescents with this condition, but this is based largely on studies of adults with the condition. The Cochrane Schizophrenia Group conducted this systematic review to synthesise the current evidence base for atypical antipsychotic medication in [read the full story…]
Atypical (second-generation) antipsychotics are used to treat a variety of psychiatric conditions. Although they have fewer side effects than first-generation antipsychotics, weight gain and other metabolic problems (such as high blood pressure and diabetes) remain common side effects of taking atypical antipsychotic medication (Mind, 2012). The Mental Elf has previously blogged about a Canadian report [read the full story…]
People using antipsychotic drugs like chlorpromazine and haloperidol get [anticholinergic] side effects such as blurred vision, dry mouth and constipation but the proportion of people experiencing these is not clear. Past surveys are very old indeed, small and not really proper surveys at all. Their results had been perpetuated for decades without verification. They were [read the full story…]
Schizophrenia according to the NICE guidelines, is a relatively common illness and in the majority of cases takes a chronic course, requiring continued management and careful attention. In the treatment and management of schizophrenia, antipsychotic medications – like olanzapine, quetiapine or clozapine – are the first line intervention. Antipsychotics can be loosely divided into “first-generation” (“typical”) and [read the full story…]
